Objective: This study evaluated a three-session acceptance-based cognitive behavioral -acceptance and commitment therapy (CBT-ACT) intervention targeting a common symptom cluster in advanced cancer-worry-insomnia-depression-fatigue.
| BACKGROUND
Patients with advanced cancer commonly experience a cluster of correlated symptoms that includes worry, sleep difficulties, depression, and fatigue. [1] [2] [3] [4] Worry can affect sleep initiation and maintenance, contributing to fatigue and depressed mood, and is especially salient for patients with low uncertainty tolerance. 3, 5 Cognitive behavioral therapy (CBT) has demonstrated efficacy for sleep, 6, 7 anxiety, 8, 9 depression, 6, 8 and fatigue 10, 11 in oncology populations. However, few CBT trials have addressed patients with advanced cancer, and adjustments to CBT may be needed for those with advanced illness. 12 Traditional CBT, which focuses on changing cognitions, may not adequately address negative thought patterns that are both distressing and realistic. For example, patients with advanced cancer typically confront functional decline and mortality. Labeling fear thoughts concerning these topics "maladaptive" is neither warranted nor useful.
Acceptance and commitment therapy (ACT), which advocates accepting emotional experience while choosing behaviors consistent with one's values, may help address these concerns. 13 ACT has demonstrated utility with cancer patients, 14 including those with advanced disease. 15 Insomnia rates for patients with advanced cancer range from 49% to 61%. 16 Sleep is often interrupted by cancer-related thoughts, as patients worry about disease progression, financial stressors, and treatment outcomes. Interventions targeting worry and uncertainty intolerance are rare and focus on healthier patients. 17 Hyperarousal, including increased psychological and physical tension, also plays a role in worry and insomnia. 18 Most CBT interventions for insomnia in cancer patients focus on behavioral sleep components (ie, sleep restriction), 6, 7 with none adapted to the specific worries, uncertainty, and hyperarousal associated with advanced disease.
Anxiety and depression are prevalent forms of distress in patients with advanced illness. 2, 3 Nevertheless, few randomized trials have utilized CBT to address anxiety among terminal cancer patients. 8 Using CBT skills (eg, relaxation and worry management), participants in a six-session intervention reported lowered anxiety compared with controls. 9 Depression in advanced disease is associated with demoralization, frustration with functional limitations, and feelings of "being a burden." 19 Yet few controlled studies have examined CBT for moodrelated distress in patients with advanced cancer. 8, 20 Fatigue, which may contribute to depressive symptoms, is pervasive among those with advanced cancer. 21 
| Sleep difficulties
Sleep difficulty was measured using the National Sleep Foundation
Sleep Diary and the Insomnia Severity Index (ISI). 24 The sleep diary includes bedtime, wake time, time-to-sleep-onset (latency), number of awakenings, wake-time-after-sleep-onset (WASO), total sleep time, and sleep inhibitors and facilitators. Napping and medication use were also assessed. Diary information was used to calculate sleep efficiency (time sleeping/time in bed), with scores greater than 0.85 representing good efficiency and scores less than 0.75 poor efficiency. 25 The ISI severity scale assesses difficulties falling asleep, staying asleep, and waking early, with higher scores indicating more severe problems. Total ISI scores of 15 or above are considered clinically significant. 24 For prepost analyses, we utilized only the three severity items (range 0-12)
because there is substantial overlap between other ISI items and oncology distress measures. Cronbach's α in the study sample was 0.82.
| Worry
Worry was assessed with the Penn State Worry Questionnaire (PSWQ), 26 which includes 16 items about worry habits, with higher scores indicating more problematic worrying. The PSWQ has good reliability and validity. 26 Scores range from 16 to 80, with scores exceeding 60 considered clinically significant. 26 Cronbach's α in the study sample was 0.95.
| Intolerance of uncertainty
Uncertainty intolerance was measured using the Intolerance of Uncertainty Scale (IUS). 27 The IUS includes 27 items concerning emotional, cognitive, and behavioral reactions to uncertainty, with scores ranging from 27 to 135. Higher scores indicate greater difficulties managing
uncertainty. The IUS has demonstrated strong construct validity. 27 Cronbach's α was 0.96 in the present study.
| Daytime sleepiness
Daytime sleepiness, or average sleep propensity, was assessed using the Epworth Sleepiness Scale (ESS), 28 consisting of eight items on which patients rate the likelihood of "dozing off" in various situations.
Total scores range from 0 to 24 with scores above 10 considered clinically significant. 28 Cronbach's α in the study sample was 0.78.
| Anxiety
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of trait and state anxiety. 29 Only the State scale was used, with scores ranging between 20 to 80. The STAI has demonstrated strong construct validity. 29 Cronbach's α in the study sample was 0.91.
| Depressive symptoms
Depressive symptoms were assessed using the Center for Epidemio- 16 and above considered clinically significant. 30 Cronbach's α in the study sample was 0.86.
| Fatigue
Fatigue was assessed using the Fatigue Symptom Inventory (FSI), 31 a 14-item scale assessing severity, frequency, and variability of fatigue, as well as interference with quality of life. Higher scores indicate greater fatigue and interference. The FSI has good construct, convergent, and discriminant validity. 31 Scores range from 0 to 70 on fatigue interference with fatigue severity greater than 3 considered clinically significant. 31 Cronbach's α was 0.90 in the current study.
| Distress
Distress was measured using the James Supportive Care Screening (JSCS), 1 which examines past-week distress related to emotional, physical, social/practical, spiritual, cognitive, and healthcare decision making/communication concerns. The scale has strong concurrent and discriminant validity. 1 This study used the emotional concerns, physical symptoms, and total scale scores. Cronbach's α was 0.92 for emotional concerns (14 items), 0.81 for physical symptoms (17 items), and 0.95 for the total scale (48 items).
| Hyperarousal
Hyperarousal was assessed using a six-item subscale of the Impact of Event Scale-Revised (IES-R), 32 which evaluates irritability, startle response, concentration problems, and hypervigilance, as well as physical reactions, such as sweating, trouble breathing, and rapid heartbeat.
Scores range from 0 to 24 with higher scores representing greater hyperarousal. Reliability and validity for the IES-R are good. 32 Cronbach's α was 0.89 for this study. 
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| Waitlist control
Participants assigned to the waitlist continued treatment as usual during the 6-week waiting period, completing questionnaires at the initial visit and 6 weeks later with no additional intervention. They were offered the intervention following this 6-week period. Per study records and chart review, none of these participants received additional psychosocial support via chaplaincy or social work during their 6-week participation. No trial symptom-related medication changes were made during this period.
| Statistical analyses
Demographic characteristics were compared across randomized groups using t tests and chi-square tests. Because repeated observations were measured within each subject, linear mixed models were used to test intervention effects while taking into account withinsubjects correlation. 33 An unstructured variance-covariance model was fitted to estimate error variance. These models were fitted using PROC MIXED in Statistical Analysis System (SAS) with REPEATED statement (SAS Institute v. 9.3). Each model included fixed effects of visit, intervention group, and their interaction. Of primary interest were preplanned contrasts comparing group changes (Visit x Group).
The Kenward-Roger adjustment to the degrees of freedom was used to control Type I error rates. 34 Overall effect size from independentgroup pretest-posttest (IGPP) design was calculated for each outcome. 35 Because the intervention was offered to control participants after the waitlist period, sensitivity analyses were performed on outcomes that had significant intervention effects by examining the tra- 3 | RESULTS
| Study population, baseline data
Baseline characteristics of the study sample are shown in Table 1 .
Groups were balanced on demographic and disease-related characteristics. Participants were primarily female and Caucasian with various advanced cancer types. There were no differences between the groups in treatments (ie, surgery, chemotherapy, and radiation) or medications for insomnia or depression. of the week, with an average of 60% adherence to sleep schedule.
| Study completion and protocol adherence
Only one participant was unable to watch the DVD due to technical problems but reviewed corresponding materials in the handbook.
| Intervention effects
Changes in sleep efficiency, sleep latency, ISI Severity, PSWQ total score, and CESD total score were significantly different between intervention and waitlist groups from baseline to week 6 ( Figure 1 ).
Mean increase in sleep efficiency for intervention participants was 9% compared with an increase of 1% for waitlist participants 
| Secondary outcomes
For secondary outcomes (see Table 2 ), there were significant differ- 
| Sensitivity analyses
Results from sensitivity analyses examining outcomes with significant effects are displayed in Table 3 . Improvements in worry, uncertainty tolerance, sleep, depression, hyperarousal, emotional distress, and total distress were observed from baseline to postintervention for the whole sample.
| Qualitative ratings and feedback
Participants rated the following elements of the intervention as most Although changes in uncertainty intolerance approached significance, this was an important finding. Uncertainty intolerance is a persistent dispositional characteristic, strongly associated with anxious distress. 27 Although no intervention study to date has lowered uncertainty intolerance among cancer patients, interventional research has linked changes in uncertainty intolerance to reduced distress in nonmedical populations. 36 The results also highlight the effectiveness of a symptom-cluster strategy. Advanced cancer patients experience an average of nine concurrent symptoms, 3 yet most CBT trials focus on isolated symptoms. Since this intervention was designed, a few additional trials have examined CBT for symptom clusters (eg, fatigue, depression, and quality of life). 37, 38 These reported significant effects, with one 38 yielding changes across multiple symptoms and another, a brief problemsolving intervention, 39 demonstrating improvement on 20-week symptom severity. Also, Kwekkeboom et al 10 piloted a brief intervention using recorded relaxation exercises and nature imagery, which yielded immediate reductions in pain, fatigue, and sleep disturbance, and reductions in symptom-cluster severity after 2 weeks. These studies highlight the utility of symptom-cluster approaches in oncology populations.
| Limitations
The study had several limitations, including the relatively small sample size and lack of diversity. Recruitment of patients with advanced disease can be challenging. Disease burden and travel excluded several patients. Coordinated medical appointments and telehealth options may help address these problems. Although the study sample mirrored the racial distribution in Ohio (85% Caucasian), future studies should recruit more diverse samples.
| Clinical implications
Most cancer-focused psychological interventions have involved patients with good prognoses, but trials focusing on early-stage illness may not address needs of those with advanced disease. This study demonstrates that a brief psychosocial intervention targeting symptoms common in advanced illness is feasible, with preliminary efficacy.
Future studies will incorporate additional strategies to address fatigue and uncertainty tolerance. Also, given the treatment barriers common in advanced cancer (eg, transportation and multiple appointments), telepsychology or web-based applications similar to those of Yanez et al 40 will be explored.
